2021
Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer
Sukumar JS, Quiroga D, Kassem M, Grimm M, Shinde NV, Appiah L, Palettas M, Stephens J, Gatti-Mays ME, Pariser A, Cherian M, Stover DG, Williams N, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B, Sardesai S. Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer. Breast Cancer Research And Treatment 2021, 190: 183-188. PMID: 34498153, PMCID: PMC8560558, DOI: 10.1007/s10549-021-06368-4.Peer-Reviewed Original ResearchConceptsOvarian function suppressionPositive breast cancerHormone receptor-positive breast cancerReceptor-positive breast cancerBreast cancerPremenopausal womenPatient preferencesPremenopausal Hormone Receptor-Positive Breast CancerAdjuvant gonadotropin‐releasing hormone analoguesHR-positive breast cancerGonadotropin-releasing hormone analogueDiscontinuation of GnRHaThird of patientsChi-square testMonthly goserelinClinical characteristicsTreatment toxicityVaginal drynessClinicopathologic characteristicsGnRH analoguesHot flashesSurgical ablationResultsA totalMedical recordsGnRHa
2018
Strategic planning for implementation of Commission on Cancer standard 3.3 in a tertiary academic center.
Klemanski D, Scharschmidt T, Ramirez M, Browning K, Ghosh-Berkebile R, Hatfield R, Schimming D, Lustberg M. Strategic planning for implementation of Commission on Cancer standard 3.3 in a tertiary academic center. Journal Of Clinical Oncology 2018, 36: 58-58. DOI: 10.1200/jco.2018.36.7_suppl.58.Peer-Reviewed Original ResearchSurvivorship care plansAcademic cancer centerAdvanced practice providersCancer RegistryEligible survivorsSCP deliveryCancer CenterTertiary academic centerJames Cancer HospitalPerformance improvement planLack of reimbursementReview eligibility criteriaElectronic medical recordsProfessional practice evaluationCurative intentEligible patientsCancer HospitalCancer survivorsTreatment summaryDisease groupMedical recordsTreatment completionProvider awarenessPractice providersCare plans
2013
Integrative model for breast cancer survivorship.
Reinbolt R, Shapiro C, Garrett J, Basinger H, Lester J, Muscari N, Ries K, Lustberg M. Integrative model for breast cancer survivorship. Journal Of Clinical Oncology 2013, 31: 132-132. DOI: 10.1200/jco.2013.31.26_suppl.132.Peer-Reviewed Original ResearchElectronic medical recordsIntegrative care modelCare plansMedical recordsCare modelCancer survivorship care planningSurvivorship care planningIndividualized care plansBreast cancer survivorshipCross-sectional studyGroup educational sessionsEarly survivorshipBetter address needsSmart phrasesMedical oncologistsPrimary nurseTreatment summaryDistress ThermometerIndividual patientsCancer survivorshipNurse practitionersCare planningBreast programPhysical symptomsPatientsDocetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review
Poi M, Berger M, Lustberg M, Layman R, Shapiro C, Ramaswamy B, Mrozek E, Olson E, Wesolowski R. Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Supportive Care In Cancer 2013, 21: 2679-2686. PMID: 23686402, PMCID: PMC3769512, DOI: 10.1007/s00520-013-1842-3.Peer-Reviewed Original ResearchConceptsBreast cancer patientsSkin toxicityCancer patientsCase seriesGranulocyte colony-stimulating factor supportToxicity eventsColony-stimulating factor supportDose-dense doxorubicinOperable stage IResultsThirty-four patientsSevere skin toxicityEvidence-based preventionElectronic medical recordsInstitutional review boardDermatologic toxicitiesDocetaxel 75Docetaxel monotherapyWeekly paclitaxelCyclophosphamide regimenClinical courseFactor supportMedical recordsTreatment strategiesGrade 3Inclusion criteria